About

Pala Garcia is a critically acclaimed violinist and an artist in residence at the University of Washington School of Music. She was recently named a 2024 National Arts Club Fellow and was featured as a leading innovative artist in the Washington Post’s “23 for ’23: Performers and Composers to Watch.” Garcia has previously served on the faculty of The Juilliard School’s Preparatory Division, taught violin and chamber music at Hunter College, and worked as a teaching artist with Carnegie Hall’s social impact programs. Alongside her spouse John Popham, she is a member, co-founder, and co-director of the chamber trio Longleash, which specializes in commissioning, performing, and curating contemporary music. The trio has performed internationally at venues such as the TIME:SPANS Festival, Kennedy Center, Kaufman Center, Noguchi Museum, National Sawdust, EMPAC, and Princeton University, among others, and their discography is available on New Focus Recordings, Innova, and New Amsterdam Records. Garcia has also appeared as a guest with ensembles including the International Contemporary Ensemble, the Orchestra of St. Luke’s, and Orpheus Chamber Orchestra, performing at stages such as Lincoln Center, Carnegie Hall, the Guggenheim Museum, the Met Museum, and others. She holds undergraduate and graduate degrees from The Juilliard School, has been a Senior Teaching Fellow at The Graduate Center, CUNY, and an Academy Fellow with the Bavarian Radio Symphony Orchestra.

Research topics

• Political Science
• Medicine
• Computer Science
• Pathology
• Nursing
• World Wide Web
• Virology
• Business
• Public relations
• Data science
• Internal medicine
• Law

Selected publications

• It is not too late to achieve global covid-19 vaccine equity

  BMJ · 2022 · 125 citations

  • Computer Science
  • Political Science
  • Computer Science

  During the covid-19 pandemic, we have seen the best of international collective action and its limits. Global scientific cooperation drove the development of safe, highly effective covid-19 vaccines in under one year. 1 Yet we have also witnessed global vaccine inequity, 2 in which low and middle income countries have "limited supply and limited vaccine brand options." 3 With the omicron wave dissipating, several well vaccinated high income nations with stockpiles of covid-19 vaccines are rushing to declare the pandemic over, reminding us of how things unfolded with tuberculosis, malaria, and HIV/AIDS in the past. But the pandemic is not over and 2.8 billion people remain completely unvaccinated. Now is the time to recommit to, and further invest in, equitable and effective country led vaccination campaigns.

  PublisherOA PDFDOI

• A multinational Delphi consensus to end the COVID-19 public health threat

  Nature · 2022 · 234 citations

  • Political Science
  • Public relations
  • Political Science

  in the management of pandemic responses. The findings of the study, which have been further endorsed by 184 organizations globally, include points of unanimous agreement, as well as six recommendations with >5% disagreement, that provide health and social policy actions to address inadequacies in the pandemic response and help to bring this public health threat to an end.

  DOI

• Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

  New England Journal of Medicine · 2020 · 2611 citations

  • Medicine
  • Internal medicine

  BACKGROUND: World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19). METHODS: We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard of care). The intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its control (drug available but patient assigned to the same care without that drug). Rate ratios for death were calculated with stratification according to age and status regarding mechanical ventilation at trial entry. RESULTS: At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan-Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P = 0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P = 0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P = 0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P = 0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration. CONCLUSIONS: These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov number, NCT04315948.).

  DOI

Recent grants

• NIH Grant U01AI034841

  NIH · $18.1M · 2007

• NIH Grant D43TW009375

  NIH · $1.8M · 2020

• NIH Grant R25TW007490

  NIH · $383k · 2012

• NIH Grant D43TW008438

  NIH · $1.1M · 2015

Frequent coauthors

• Gonzalo Pérez

  1012 shared

• Suzanne M. Garland

  University of Melbourne

  1011 shared

• Darron R. Brown

  Indiana University – Purdue University Indianapolis

  1011 shared

• Luisa L. Villa

  Instituto do Câncer do Estado de São Paulo

  1010 shared

• Susanne K. Kjær

  Rigshospitalet

  1010 shared

• Joakim Dillner

  1010 shared

• Jorma Paavonen

  University of Helsinki

  1009 shared

• Sławomir Majewski

  Medical University of Warsaw

  1009 shared

Awards & honors

• 2024 National Arts Club Fellow
• Featured as a leading innovative artist in the Washington Po…

Similar researchers at University of Washington

• Sarah Jaewon Leeh-151
• Jan Hansenh-130
• Linda Simonsenh-120
• Anna Waldh-119
• Jesse Bloomh-117